Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> GPCR/G protein >> Ras

Ras

Ras belongs to a class of small GTPase and is involved in transmitting signals within cells.

Products for  Ras

  1. Cat.No. Product Name Information
  2. GC64657 (E/Z)-ZINC09659342 (E/Z)-ZINC09659342 is an inhibitor of Lbc-RhoA interaction. (E/Z)-ZINC09659342 Chemical Structure
  3. GC19541 (rac)-Antineoplaston A10

    (rac)-Antineoplaston A10 is the racemate of Antineoplaston A10

     (rac)-Antineoplaston A10 Chemical Structure
  4. GC69904 (S)-JDQ-443

    (S)-JDQ-443 is an isomer of JDQ-443. JDQ-443 is an orally effective and selective covalent KRAS G12C inhibitor. JDQ-443 has anti-tumor activity.

     (S)-JDQ-443 Chemical Structure
  5. GC32770 1A-116 1A-116, a potent Rac1 inhibitor, is specific for W56 residues, can prevent EGF-induced Rac1 activation and block Rac1-P-Rex1 interaction. 1A-116 can induce apoptosis and inhibit cell proliferation, migration and cycle progression in a concentration-dependent manner. 1A-116 also demonstrates a high antimetastatic activity in vivo. 1A-116 Chemical Structure
  6. GC15478 6H05 K-Ras inhibitor 6H05 Chemical Structure
  7. GC60533 6H05 (TFA) An allosteric inhibitor of oncogenic K-Ras(G12C) 6H05 (TFA) Chemical Structure
  8. GC34427 6H05 trifluoroacetate (K-Ras inhibitor) 6H05 trifluoroacetate (K-Ras inhibitor) Chemical Structure
  9. GC19546 AMG-510 racemate Sotorasib (AMG-510) racemate is the racemate of Sotorasib (AMG-510). AMG-510 is a potent, orally bioavailable, and selective KRAS G12C covalent inhibitor with anti-tumor activity. AMG-510 racemate Chemical Structure
  10. GC35361 Antineoplaston A10 Antineoplaston A10, a naturally occurring substance in human body, is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer. Antineoplaston A10 Chemical Structure
  11. GC34114 ARS-1323 ARS-1323, the racemate of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1. ARS-1323 Chemical Structure
  12. GC65480 ARS-1323-alkyne ARS-1323-alkyne, a switch-II pocket (S-IIP) inhibitor, is a conformational specific chemical reporter of KRASG12C nucleotide state in living cells. ARS-1323-alkyne Chemical Structure
  13. GC34055 ARS-1620 ARS-1620 is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics. ARS-1620 Chemical Structure
  14. GC34091 ARS-1630 ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1. ARS-1630 Chemical Structure
  15. GC19037 ARS-853 ARS-853 is a selective, covalent KRASG12C inhibitor with an IC50 of 2.5 uM. ARS-853 Chemical Structure
  16. GC64341 ASP2453 ASP2453 is a potent, selective and covalent KRAS G12C inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC50 value of 40 nM. ASP2453 Chemical Structure
  17. GC46893 Atranorin A depside lichen metabolite with diverse biological activities Atranorin Chemical Structure
  18. GC33186 BAY-293 An inhibitor of the K-Ras-SOS1 protein-protein interaction BAY-293 Chemical Structure
  19. GC33340 BDP9066 BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation. BDP9066 Chemical Structure
  20. GC35513 BI-2852 BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based drug design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D?versus KRASwt?(740?nM vs 7.5?μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells. BI-2852 Chemical Structure
  21. GC68760 BI-2865

    BI-2865 is a non-covalent pan-KRAS inhibitor. BI-2865 binds to KRAS WT, G12C, G12D, G12V and G13D mutants with KD values of 6.9, 4.5, 32, 26 and 4.3 nM respectively. BI-2865 inhibits the proliferation of BaF3 cells expressing KRAS G12C, G12D or G12V mutations (average IC50: approximately 140 nM).

     BI-2865 Chemical Structure
  22. GC10612 BQU57 Derivative of RBC8 BQU57 Chemical Structure
  23. GC16692 Casin GTPase Cdc42 inhibitor Casin Chemical Structure
  24. GC14266 CCG 203971

    Antifibrotic agent

     CCG 203971 Chemical Structure
  25. GC12795 CCG-1423 RhoA inhibitor CCG-1423 Chemical Structure
  26. GC38898 CCG-222740 CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor. CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis. CCG-222740 Chemical Structure
  27. GC12948 CID-1067700

    competitive inhibitor of nucleotide binding by Ras-related GTPases

     CID-1067700 Chemical Structure
  28. GC62347 CMC2.24 CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 Chemical Structure
  29. GC13076 Deltarasin A KRAS inhibitor Deltarasin Chemical Structure
  30. GC12060 Deltarasin hydrochloride inhibitor of KRAS-PDEδ interaction, potent and selective Deltarasin hydrochloride Chemical Structure
  31. GC35859 Diazepinomicin Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models. Diazepinomicin Chemical Structure
  32. GC65270 Digeranyl bisphosphonate Digeranyl bisphosphonate (DGBP) is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1. Digeranyl bisphosphonate Chemical Structure
  33. GC10030 EHop-016 Rac1/Rac3 GTPase inhibitor,potent and specific EHop-016 Chemical Structure
  34. GC10660 EHT 1864 Rac family small GTPases inhibitor EHT 1864 Chemical Structure
  35. GC66473 ESI-08 ESI-08 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC50 of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation. ESI-08 Chemical Structure
  36. GC64723 Garsorasib Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential for the research of various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (non-small cell lung cancer) (extracted from patent WO2020233592A1, compound 2). Garsorasib Chemical Structure
  37. GC64510 GDC-6036 GDC-6036 (compound 17a) is a potent K-Ras G12C inhibitor with an IC50 of <0.01 μM. GDC-6036 has an EC50 of 2 nM in K-Ras G12C-alkylation HCC1171 cells. GDC-6036 Chemical Structure
  38. GC68004 GDC-6036-NH GDC-6036-NH Chemical Structure
  39. GC64216 GGTI-286 GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276. GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM. GGTI-286 Chemical Structure
  40. GC64784 GGTI-286 hydrochloride GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276. GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM. GGTI-286 hydrochloride Chemical Structure
  41. GC36134 GGTI298 GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC50 values of 3 and > 20 μM in vivo, respectively. GGTI298 Chemical Structure
  42. GC19164 GGTI298 Trifluoroacetate

    GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC50 of 3 uM; little effect on Ha-Ras with IC50 of >20 uM.

     GGTI298 Trifluoroacetate Chemical Structure
  43. GC63564 JDQ-443 JDQ-443 is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). JDQ-443 shows antitumor activity. JDQ-443 Chemical Structure
  44. GC36398 K-Ras G12C-IN-1 K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1. K-Ras G12C-IN-1 Chemical Structure
  45. GC36399 K-Ras G12C-IN-2 K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor. K-Ras G12C-IN-2 Chemical Structure
  46. GC36400 K-Ras G12C-IN-3 K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C. K-Ras G12C-IN-3 Chemical Structure
  47. GC62622 K-Ras G12C-IN-4 K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRASG12C. K-Ras G12C-IN-4 Chemical Structure
  48. GC12247 K-Ras(G12C) inhibitor 12 allosteric inhibitor of K-Ras(G12C) K-Ras(G12C) inhibitor 12 Chemical Structure
  49. GC33153 K-Ras-IN-1 K-Ras-IN-1 is a K-Ras inhibitor. K-Ras-IN-1 binds to K-Ras (WT), K-Ras (G12D), K-Ras (G12V), and H-Ras. K-Ras-IN-1 has potential for the research of pancreatic, colon and lung carcinomas. K-Ras-IN-1 Chemical Structure
  50. GC16922 Kobe0065 Ras inhibitor Kobe0065 Chemical Structure
  51. GC11204 kobe2602 Ras inhibitor kobe2602 Chemical Structure
  52. GC64558 KRA-533 KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells. KRA-533 Chemical Structure
  53. GC34198 KRas G12C inhibitor 1 KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1. KRas G12C inhibitor 1 Chemical Structure
  54. GC36397 KRAS G12C inhibitor 13 KRAS G12C inhibitor 13 is a KRAS G12C inhibitor extracted from patent WO2018143315A1, compound 30. KRAS G12C inhibitor 13 Chemical Structure
  55. GC64442 KRAS G12C inhibitor 14 KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 17, has an IC50 of 18 nM. KRAS G12C inhibitor 14 Chemical Structure
  56. GC63875 KRAS G12C inhibitor 15 KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 22, has an IC50 of 5 nM. KRAS G12C inhibitor 15 Chemical Structure
  57. GC34188 KRas G12C inhibitor 2 KRas G12C inhibitor 2 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1. KRas G12C inhibitor 2 Chemical Structure
  58. GC65904 KRAS G12C inhibitor 28 KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC50 of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1). KRAS G12C inhibitor 28 Chemical Structure
  59. GC34196 KRas G12C inhibitor 3 KRas G12C inhibitor 3 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1. KRas G12C inhibitor 3 Chemical Structure
  60. GC34192 KRas G12C inhibitor 4 KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1. KRas G12C inhibitor 4 Chemical Structure
  61. GC34162 KRAS G12C inhibitor 5 KRAS G12C inhibitor 5 is a KRas G12C inhibitor extracted from patent WO2017201161A1, Compound example 147. KRAS G12C inhibitor 5 Chemical Structure
  62. GC62227 KRAS G12D inhibitor 1 KRAS G12D inhibitor 1 (example 243) is a KRAS G12D inhibitor, with an IC50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation. KRAS G12D inhibitor 1 Chemical Structure
  63. GC69339 KRAS G12D inhibitor 14

    KRAS G12D inhibitor 14 is an effective inhibitor of KRAS G12D, with a binding affinity (KD) to the KRAS G12D protein of 33 nM. It reduces the activity of KRAS G12D (KRAS G12D-GTP), but does not reduce that of KRAS G13D.

     KRAS G12D inhibitor 14 Chemical Structure
  64. GC62486 KRAS inhibitor-10 KRAS inhibitor-10 selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a?tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1. KRAS inhibitor-10 Chemical Structure
  65. GC60969 KRAS inhibitor-9 KRAS inhibitor-9, a potent KRAS inhibitor (Kd=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells. KRAS inhibitor-9 Chemical Structure
  66. GC64447 KRpep-2d KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research. KRpep-2d Chemical Structure
  67. GC65032 KRpep-2d TFA KRpep-2d (TFA) is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research. KRpep-2d TFA Chemical Structure
  68. GC61766 LC-2 LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM. LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines. LC-2 Chemical Structure
  69. GC10265 Manumycin A

    farnesyltransferase inhibitor

     Manumycin A Chemical Structure
  70. GC32970 MBQ-167 MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively. MBQ-167 Chemical Structure
  71. GC36599 Methylophiopogonanone B An isoflavone with diverse biological activities Methylophiopogonanone B Chemical Structure
  72. GC14800 ML 141 Cdc42 GTPase inhibitor ML 141 Chemical Structure
  73. GC13315 ML-098 activator of the GTP-binding protein Rab7 ML-098 Chemical Structure
  74. GC61076 MLS000532223 MLS000532223 is a high affinity, selective inhibitor of Rho family GTPases, with EC50 values ranging from 16 μM to 120 μM. MLS000532223 prevents GTP binding to several GTPases. MLS000532223 Chemical Structure
  75. GC69498 MRTF/SRF-IN-1

    MRTF/SRF-IN-1 (example 41) is an inhibitor of myocardin-related transcription factor and serum response factor (MRTF/SRF). MRTF/SRF-IN-1 can be used for research on cancer prevention and fibrosis.

     MRTF/SRF-IN-1 Chemical Structure
  76. GC64964 MRTX-1257 MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells. MRTX-1257 Chemical Structure
  77. GC64452 MRTX-EX185 MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and KRAS(G12D), with an IC50 of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS. MRTX-EX185 Chemical Structure
  78. GC64365 MRTX0902 MRTX0902 is an orally active and potent SOS1 inhibitor with an IC50 of 46 nM (WO2021127429A1; Example 12-10). MRTX0902 Chemical Structure
  79. GC62699 MRTX1133

    MRTX1133 is an exceptionally potent and selective KRASG12D inhibitor with high affinity (<2nM).

     MRTX1133 Chemical Structure
  80. GC63079 MRTX1133 formic MRTX1133 formic Chemical Structure
  81. GC38400 MRTX849 MRTX849 (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. MRTX849 covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction. MRTX849 Chemical Structure
  82. GC10069 NSC 23766 trihydrochloride Selective inhibitor of Rac1-GEF interaction. NSC 23766 trihydrochloride Chemical Structure
  83. GC14860 Oncrasin 1 An anticancer agent Oncrasin 1 Chemical Structure
  84. GC69653 Pan KRas-IN-1

    Pan KRas-IN-1 is a pan-KRas inhibitor that can be used for studying cancer resistance to KRas G12C inhibitors.

     Pan KRas-IN-1 Chemical Structure
  85. GC32716 Pan-RAS-IN-1 Pan-RAS-IN-1 is a pan-Ras inhibitor that disrupts the interaction of Ras proteins and their effectors. Pan-RAS-IN-1 Chemical Structure
  86. GC36901 PHT-7.3 PHT-7.3 is a selective inhibitor of connector enhancer of kinase suppressor of Ras 1 (Cnk1) pleckstrin homology (PH) domain (Kd=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity. PHT-7.3 Chemical Structure
  87. GC38942 PROTAC K-Ras Degrader-1 PROTAC K-Ras Degrader-1 (Compound 518) is potent K-Ras degrader based on Cereblon E3 ligand, exhibits ≥70% degradation efficacy in SW1573 cells. PROTAC K-Ras Degrader-1 Chemical Structure
  88. GC10015 Rac1 Inhibitor W56 inhibitor of Rac1 interaction with Rac1-specific GEFs TrioN, GEF-H1 and Tiam1 Rac1 Inhibitor W56 Chemical Structure
  89. GC62421 RAS inhibitor Abd-7 RAS inhibitor Abd-7, a potent RAS-binding compound (Kd=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V. RAS inhibitor Abd-7 Chemical Structure
  90. GC62504 RAS/RAS-RAF-IN-1 RAS/RAS-RAF-IN-1 is a potent RAS and RAS-RAF inhibitor. RAS/RAS-RAF-IN-1 has a KD of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity. RAS/RAS-RAF-IN-1 Chemical Structure
  91. GC63647 Rasarfin Rasarfin is a dual Ras and ARF6 inhibitor. Rasarfin Chemical Structure
  92. GC66001 RBC10 RBC10 is an anti-cancer agent. RBC10 inhibits the binding of Ral to its effector RALBP1. RBC10 also inhibits Ral-mediated cell spreading of murine embryonic fibroblasts and anchorage-independent growth of human cancer cell lines. RBC10 Chemical Structure
  93. GC10906 RBC8 Ral GTPase inhibitor RBC8 Chemical Structure
  94. GC33167 Rhosin Rhosin is a potent, specific RhoA subfamily Rho GTPases inhibitor, which specifically binds to RhoA to inhibit RhoA-GEF interaction with a Kd of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin induces cell apoptosis. Rhosin promotes stress resiliency through enhancing D1-MSN plasticity and reducing hyperexcitability. Rhosin Chemical Structure
  95. GC32729 Rhosin hydrochloride Rhosin hydrochloride is a potent, specific RhoA subfamily Rho GTPases inhibitor. Rhosin hydrochloride specifically binds to RhoA to inhibit RhoA-GEF interaction with a Kd of ~ 0.4 uM, and does not interact with Cdc42 or Rac1, nor the GEF, LARG. Rhosin hydrochloride induces cell apoptosis. Rhosin hydrochloride promotes stress resiliency through enhancing D1-MSN plasticity and reducing hyperexcitability. Rhosin hydrochloride Chemical Structure
  96. GC63562 RM-018 RM-018 is a potent, functionally distinct tricomplex KRASG12C active-state inhibitor. RM-018 retains the ability to bind and inhibit KRASG12C/Y96D and could overcome resistance. RM-018 binds specifically to the GTP-bound, active [“RAS(ON)”] state of KRASG12C. RM-018 Chemical Structure
  97. GC62494 RMC-0331 RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction. RMC-0331 Chemical Structure
  98. GC69822 RMC-6291

    RMC-6291 is an orally effective covalent inhibitor of KRASG12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Therefore, RMC-6291 blocks the signaling of KRASG12C(ON) by spatially obstructing the binding of RAS effectors. RMC-6291 produces profound and sustained inhibition of the RAS pathway activity in KRASG12C tumor models.

     RMC-6291 Chemical Structure
  99. GC50609 SAH-SOS1A KRas/SOS1 interaction inhibitor SAH-SOS1A Chemical Structure
  100. GC10528 Salirasib A Ras inhibitor with anti-cancer and anti-atherogenic activity Salirasib Chemical Structure
  101. GC65263 SOS1-IN-11 SOS1-IN-11 is a potent SOS1 inhibitor with an IC50 value of 30 nM. SOS1-IN-11 Chemical Structure

Items 1 to 100 of 108 total

per page
  1. 1
  2. 2

Set Descending Direction